Thought Leadership

The Problem with Copay Adjustment and Alternate Funding Programs

February

23

2023

Key Insights

  • Copay accumulator and maximizer programs are widespread. Our research shows that payers covering 75% of lives implemented at least one such program before 2022. These payers report that approximately 40% of their plan sponsors have adopted an accumulator or maximizer, a share expected to rise.
  • Patients are caught in the middle, as these programs can drive down adherence and deplete manufacturers’ patient assistance reserves. In some cases, they cost patients more than double what they would have paid otherwise.
  • Specialty carve-out programs add another layer of risk, with payers reporting delays in therapy starts and raising ethical concerns about depleting funds meant for people in need. Manufacturers are pushing back with updated coupon terms, direct patient payments and adherence data.

Payers’ use of copay adjustment programs has exploded over the past few years, and interest in them remains high. In addition, payers are now looking to bring down their drug spend by adopting newer strategies offered by companies with alternate funding programs. While many manufacturers are pushing back against these copay adjustment and specialty carve-out programs, patients remain caught in the middle.

Detrimental Impact on Patients

Normally, when a manufacturer provides copay assistance for a drug, that dollar amount of that assistance counts toward a patient’s deductible and out-of-pocket maximum. Patients benefit from reduced out-of-pocket costs for their prescription while fulfilling their deductible more rapidly.

With copay accumulators, the maximum manufacturer assistance is applied up front; once those funds are depleted, the patient must pay the full cost of the medication for the remainder of the year. The manufacturer’s payments do not count toward members’ deductibles and out-of-pocket maximums. By contrast, copay maximizer programs distribute 100% of available manufacturer copay offset funds over 12 months.

For a long time, health plans and PBMs condemned manufacturer patient-assistance programs, accusing them of inducing patients to take more costly drugs. While these programs offer patients financial relief, some payers argue that they also encourage patients to pick higher-priced brand-name medications over more affordable generics—effectively sidestepping the structure and intent of the health plan’s formulary.

That perception began to change with the introduction of accumulators in 2017, followed by maximizers a little while later. These programs are designed to prevent manufacturer assistance from counting toward a patient’s deductible or out-of-pocket maximum, allowing health plans or their partnered vendors to redirect portions of this financial aid. In practice, this means a significant slice of copay support that was once intended to ease patients’ burden is now absorbed by the payer system instead.

A 2022 PSG report found that 65% of benefits leaders believe copay assistance programs are a good strategy for helping plan sponsors save money, up from 28% four years prior.

Unfortunately, numerous studies reveal that these programs often harm patients instead of helping them. Once the manufacturer assistance dries up, many people struggle to pay their out-of-pocket obligations for treatment, driving down adherence and threatening their health. In some cases, these programs can end up costing patients more than double what they would have paid otherwise. Such programs also deplete the overall reserves that manufacturers have set aside for patient assistance programs, potentially impacting companies’ ability to offer such support.

Widespread Adoption of Predatory Programs

With the industry’s increased focus on reducing the impact of high-cost drugs, these programs are proliferating. In the fall of 2022, MMIT surveyed 35 payers covering 121.5 million commercial lives regarding their use of copay accumulators and maximizers. Payers covering 75% of lives had implemented at least one maximizer or accumulator program prior to 2022.

Payers with 16% of lives launched an accumulator program in 2022, while those covering 1% of lives said they had plans to do so in the future. While none of the respondents implemented a maximizer program in 2022, those representing 13% of lives said they planned to do so at a later date. Payers with only 10% of lives said they had no plans to implement a copay accumulator, and payers covering 11% said the same about maximizers.

Payers with these programs in place also said that about 40% of their plan sponsors have implemented an accumulator or maximizer, with that percentage expected to increase in the next year.

The Rise of Specialty Carve-Out Programs

In addition to copay accumulator and maximizer programs, specialty carve-out programs are becoming popular. Run by alternate funding companies, these programs may require payers to exclude certain specialty drugs from their coverage; these drugs are instead covered via patient assistance programs run by manufacturers or charitable foundations. If patients are denied patient assistance, coverage reverts to the company’s payer/PBM/specialty pharmacy. And if patients do not enroll in these programs, they often are subjected to exorbitant out-of-pocket costs for the excluded agents.

According to the PSG report, 8% of benefits leaders said they had an alternative funding model in place, while 31% said they were exploring their use. A survey from Gallagher Research & Insights found that 10% of self-insured employers with at least 5,000 U.S. employees used alternative funding vendors in 2022, 8% said they are planning to use them within two years, and 19% said they will be considering their use in three to five years.

But some payers responding to the MMIT survey expressed ethical concerns over the act of depleting funds that have been allocated for people who truly need them. In addition, they reported delays in therapy, which can pose a threat to patient health. As with accumulators and maximizers, the carve-outs can put the sustainability of manufacturer assistance programs at risk.

Prohibitive Legislation and Pharma Pushback

Manufacturers do not have many recourses to deter the use of carve-outs, other than educating companies that their savings may not be as substantial as they anticipate. However, both state governments and pharma companies have acted to tamp down the use of accumulators and maximizers.

Numerous states have outright banned the use of accumulators: By January 2023, 16 states had passed such legislation. But these laws are applicable to state-regulated health plans only and do not affect self-funded groups. Lawsuits over these programs have been filed, one by a manufacturer and another by three patient advocacy groups.

Some manufacturers have pushed back by changing their terms and conditions concerning manufacturer coupons, explicitly specifying that beneficiaries with a maximizer benefit design are not eligible for copay cards. One insurer estimated that the nine drugs affected by this approach from two manufacturers would affect “approximately 40% of historical savings.” Other drugmakers have begun to limit the amount of available funds.

Pharma companies are also finding ways to pay patients directly, perhaps via prepaid debit cards or checks. And some are collecting data on how accumulators and maximizers may impact adherence to get a better understanding of how these initiatives are affecting patients’ use of their prescribed medications. They hope this data can persuade payers of the drawbacks of such programs.

While state-level action is on the rise, the broader regulatory landscape remains fragmented. Many self-insured employers and large group health plans, which fall outside state regulation, are still able to implement accumulator and maximizer programs. Federal guidance and oversight remain limited, creating significant gaps in protections for patients, who may be left with unpredictable and at times, burdensome out-of-pocket costs. This patchwork has led to several challenges:

  • Lack of Transparency: Patients often find it difficult to determine whether their plan uses an accumulator or maximizer, leading to confusion at the pharmacy counter.
  • Variable Protections: Depending on whether a plan is state-regulated or self-funded, patients’ experiences with copay assistance can differ dramatically, leaving many vulnerable to higher costs.
  • Ethical Concerns: Stakeholders are increasingly scrutinizing the ethical and legal implications of cost-shifting programs, particularly as they relate to patient access and equity.

In the meantime, manufacturers must be aware of the growing threat posed by these copay adjustment and specialty carve-out programs and take steps to limit their financial risk. 

MMIT recently fielded a special report to survey payers on the future of copay accumulators and maximizers. Learn more via MMIT’s Oncology Index or Biologics & Injectables Index for non-oncology products.

Frequently Asked Questions

What are copay accumulators and maximizers, and how do they differ?

Normally, manufacturer copay assistance counts toward a patient’s deductible and out-of-pocket maximum. With a copay accumulator, the maximum manufacturer assistance is applied up front and doesn’t count toward those limits; once the funds run out, the patient must pay the full cost of the medication for the rest of the year. Maximizers instead distribute 100% of available manufacturer copay offset funds over 12 months.

How do copay adjustment programs affect patients?

Once manufacturer assistance dries up, many patients struggle with their out-of-pocket obligations, which drives down adherence and threatens their health. In some cases, these programs can cost patients more than double what they would have paid otherwise. They also deplete the reserves manufacturers have set aside for patient assistance, which may affect companies’ ability to offer such support.

How common are copay accumulators and maximizers?

In MMIT’s fall 2022 survey, payers covering 75% of lives had implemented at least one accumulator or maximizer program prior to 2022. Payers with 16% of lives launched an accumulator in 2022, and those with 13% of lives planned to launch a maximizer at a later date. Only payers with 10% of lives had no plans for an accumulator, and payers with 11% had no plans for a maximizer.

What are specialty carve-out programs?

Run by alternate funding companies, these programs may require payers to exclude certain specialty drugs from coverage, with the drugs instead covered through patient assistance programs run by manufacturers or charitable foundations. If a patient is denied assistance, coverage reverts to the payer, PBM or specialty pharmacy, and patients who don’t enroll often face exorbitant out-of-pocket costs for the excluded drugs. Some payers in MMIT’s survey raised ethical concerns about depleting funds allocated for people who truly need them, and reported delays in therapy.

How are manufacturers and states responding?

Some manufacturers have changed coupon terms to exclude patients with a maximizer benefit design, limited available funds, or begun paying patients directly via prepaid debit cards or checks. Some are also collecting data on how these programs affect adherence in the hope of persuading payers of their drawbacks. States have taken action as well, but those laws apply only to state-regulated plans and don’t cover self-funded groups, and lawsuits have been filed by a manufacturer and by patient advocacy groups.

Seamus Cole

Seamus Cole

Seamus Cole is a Consultant in Advisory Services at MMIT.

Related Posts
Payers and PBMs Are Excluding Cancer Drugs at a Growing Rate. How Can Manufacturers Prepare?
December 1

Payers and PBMs Are Excluding Cancer Drugs at a Growing Rate. How Can Manufacturers Prepare?

Read More
What’s Ahead for Market Access in 2023?
January 5

What’s Ahead for Market Access in 2023?

Read More
Related Posts

Rebates Take the First Hit: How MFN Pricing Is Reshaping Payer Strategy

whats-shaping-coverage-under-medicare-drug-price-negotiation

Competition, Not Discounts: What’s Shaping Coverage Under Medicare Drug Price Negotiation

glp-1s-crossroads-access-innovation

GLP-1s at a Crossroads: Access and Innovation

Payers and PBMs Are Excluding Cancer Drugs at a Growing Rate. How Can Manufacturers Prepare?

Payers and PBMs Are Excluding Cancer Drugs at a Growing Rate. How Can Manufacturers Prepare?

What’s Ahead for Market Access in 2023?

What’s Ahead for Market Access in 2023?

Topics
Stay In Touch

Be the first to know about new arrivals and promotions

NEW RELEASE: The State of Patient Access 2026